382 related articles for article (PubMed ID: 18178506)
1. [Anticholinergic drugs in overactive bladder].
Muhlstein J; Deval B
Gynecol Obstet Fertil; 2008 Jan; 36(1):90-6. PubMed ID: 18178506
[TBL] [Abstract][Full Text] [Related]
2. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
MacDiarmid SA
BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
[TBL] [Abstract][Full Text] [Related]
3. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic receptor antagonists for overactive bladder.
Abrams P; Andersson KE
BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
Staskin DR; Te AE
BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
7. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
10. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T
Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651
[TBL] [Abstract][Full Text] [Related]
11. Newer agents for the management of overactive bladder.
Epstein BJ; Gums JG; Molina E
Am Fam Physician; 2006 Dec; 74(12):2061-8. PubMed ID: 17186712
[TBL] [Abstract][Full Text] [Related]
12. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
Ko Y; Malone DC; Armstrong EP
Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
[TBL] [Abstract][Full Text] [Related]
14. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
15. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.
Coyne KS; Sexton CC; Irwin DE; Kopp ZS; Kelleher CJ; Milsom I
BJU Int; 2008 Jun; 101(11):1388-95. PubMed ID: 18454794
[TBL] [Abstract][Full Text] [Related]
16. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
17. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
18. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
19. Role of muscarinic receptor antagonists in urgency and nocturia.
Michel MC; de la Rosette JJ
BJU Int; 2005 Sep; 96 Suppl 1():37-42. PubMed ID: 16083453
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]